Trimipramine maleate

Fluoxetine, TAPI-1, SB271046, SB742457, L-685,458 and roscovitine were purchased from Selleck Chemicals. Amitriptyline hydrochloride, ST1936 and SB258585 were from Tocris Bioscience. Protriptyline hydrochloride, amoxapine, trimipramine maleate, SB215505, SB206553, cAMP, L-ascorbic acid and DAPI were purchased from Sigma. Escitalopram oxalate was purchased from Lundbeck. Sertraline hydrochloride was from Pfizer. BACE inhibitor IV (BSI IV) was from Calbiochem. Recombinant human BDNF, GNDF, and IGF-I were from Peprotech. CellTiter-Glo was from Promega. Immunoblotting was performed with the following antibodies: anti-ADAM10 (Ab1997, Abcam), anti-BACE1 N-termimus (AP7774b, Abgent), anti-APP-CTF (A8717, Sigma), anti-actin (A2066, Sigma), anti-CDK5 (sc-173, Santa Cruz), and Rabbit anti-β-arrestin-1/2 (A1CT) antibody was a kind gift from Dr. Robert J. Lefkowitz. Immunofluorescence staining was performed with the following primary antibodies: anti-Tuj1 (801201, BioLegend), anti-Sox2 (sc-17320, Santa Cruz), anti-Map2 (Ab5622, Millipore), and anti-GFAP (sc-6170, Santa Cruz).

The FDA Pharmakon compound library was purchased from MicroSource Discovery Systems, Inc. (USA). Compounds (10 mM, dissolved in DMSO) were stored at -80 °C until use. Levamisole and ivermectin, used for the in vitro controls, were purchased from Fluka and Sigma-Aldrich, respectively (Buchs, Switzerland), dissolved at 10 mM stock solutions in DMSO, and stored at -20 °C until further use. For the in vivo studies, bitoscanate, chlorcyclizine HCl, clemastine, dicyclomine HCl, drofenine HCl, ethopropazine HCl, lansoprazole, metformin HCl, morantel, natamycin, trichlorfon, and trimipramine maleate were purchased from Sigma-Aldrich.